263 related articles for article (PubMed ID: 15211329)
1. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit.
Ridker PM
Am Heart J; 2004 Jul; 148(1 Suppl):S19-26. PubMed ID: 15211329
[TBL] [Abstract][Full Text] [Related]
2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
3. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment.
Libby P; Ridker PM
Am J Med; 2004 Mar; 116 Suppl 6A():9S-16S. PubMed ID: 15050187
[TBL] [Abstract][Full Text] [Related]
4. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
Kones R
Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
[TBL] [Abstract][Full Text] [Related]
5. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
Stewart RA
Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
[TBL] [Abstract][Full Text] [Related]
6. The JUPITER trial: How will it change clinical practice?
Watson KE
Rev Cardiovasc Med; 2009; 10(2):91-6. PubMed ID: 19593321
[TBL] [Abstract][Full Text] [Related]
7. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
Ridker PM; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Khurmi NS; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Am J Cardiol; 2007 Dec; 100(11):1659-64. PubMed ID: 18036365
[TBL] [Abstract][Full Text] [Related]
8. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
Fonseca FA; Izar MC
Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy.
Lee KK; Cipriano LE; Owens DK; Go AS; Hlatky MA
Circulation; 2010 Oct; 122(15):1478-87. PubMed ID: 20876434
[TBL] [Abstract][Full Text] [Related]
10. Role of C-reactive protein in coronary risk reduction: focus on primary prevention.
Gotto AM
Am J Cardiol; 2007 Mar; 99(5):718-25. PubMed ID: 17317380
[TBL] [Abstract][Full Text] [Related]
11. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
[TBL] [Abstract][Full Text] [Related]
12. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
[TBL] [Abstract][Full Text] [Related]
13. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease.
Haffner SM
Am J Cardiol; 2006 Jan; 97(2A):3A-11A. PubMed ID: 16442931
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein: a novel marker of cardiovascular risk.
Shah SH; Newby LK
Cardiol Rev; 2003; 11(4):169-79. PubMed ID: 12852794
[TBL] [Abstract][Full Text] [Related]
15. [Inflammation and C-reactive protein in cardiovascular disease].
Munk PS; Larsen AI
Tidsskr Nor Laegeforen; 2009 Jun; 129(12):1221-4. PubMed ID: 19521445
[TBL] [Abstract][Full Text] [Related]
16. Markers of inflammation and cardiovascular disease: clinical applications of C-reactive protein determination.
Martínez VB; González-Juanatey JR
Am J Cardiovasc Drugs; 2009; 9 Suppl 1():3-7. PubMed ID: 20000881
[TBL] [Abstract][Full Text] [Related]
17. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
Koenig W
Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
[TBL] [Abstract][Full Text] [Related]
18. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.
Krane V; Winkler K; Drechsler C; Lilienthal J; März W; Wanner C;
Am J Kidney Dis; 2009 Nov; 54(5):902-11. PubMed ID: 19781835
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
Sabatine MS; Morrow DA; Jablonski KA; Rice MM; Warnica JW; Domanski MJ; Hsia J; Gersh BJ; Rifai N; Ridker PM; Pfeffer MA; Braunwald E;
Circulation; 2007 Mar; 115(12):1528-36. PubMed ID: 17372173
[TBL] [Abstract][Full Text] [Related]
20. C-reactive protein: a new risk assessment tool for cardiovascular disease.
Clearfield MB
J Am Osteopath Assoc; 2005 Sep; 105(9):409-16. PubMed ID: 16239491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
